Expert Interview
A Second Look: Exploring Agios' Mitapivat’s Role in Managing Transfusion-Dependent and Non–Transfusion-Dependent Thalassemia
Ticker(s): AGIOInstitution: Harvard
Associate Professor at Harvard Medical School, serving as Executive Editor of Hematology: The ASH Education Program and contributing to global hematology advancements.
Hematologist and Co-Director of the MGH Hereditary Hemorrhagic Telangiectasia Center of Excellence, specializing in bleeding, clotting, and hemolytic disorders at Massachusetts General Hospital.
NIH-funded clinical investigator leading trials on novel therapies for immune thrombocytopenia, hereditary hemolytic anemias, and HHT, with over 140 peer-reviewed publications.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
